{"log_id": 8766255196584531700, "direction": 0, "words_result_num": 10, "words_result": [{"probability": {"variance": 0, "average": 0.999971, "min": 0.999971}, "location": {"width": 22, "top": 108, "height": 23, "left": 1142}, "words": "件"}, {"probability": {"variance": 0.000155, "average": 0.993919, "min": 0.942808}, "location": {"width": 815, "top": 231, "height": 29, "left": 213}, "words": "次至240周的富马酸替诺福韦二吡呋酯累积基因型耐药评估。研究0102和0103核苷"}, {"probability": {"variance": 0.000105, "average": 0.99622, "min": 0.940657}, "location": {"width": 806, "top": 274, "height": 29, "left": 215}, "words": "初治人群中, Hbeag阳性受试者基线病毒载量高于 Hbeag阴性受试者,并且在富马酸"}, {"probability": {"variance": 2.3e-05, "average": 0.99739, "min": 0.975234}, "location": {"width": 788, "top": 318, "height": 28, "left": 215}, "words": "替诺福韦二吡呋酯单药治疗末次给药时间点时仍呈现病毒血症受试者比率显著较高"}, {"probability": {"variance": 4.1e-05, "average": 0.995355, "min": 0.978603}, "location": {"width": 167, "top": 362, "height": 26, "left": 224}, "words": "(分别为15%和4%"}, {"probability": {"variance": 0.001732, "average": 0.985618, "min": 0.797253}, "location": {"width": 834, "top": 403, "height": 45, "left": 259}, "words": "仍呈现病毒血症受试者的HBV分离株显示有治疗期间出现的突变(表15);但是"}, {"probability": {"variance": 2.8e-05, "average": 0.996707, "min": 0.978383}, "location": {"width": 888, "top": 439, "height": 39, "left": 214}, "words": "并未出现发生率高且与富马酸替诺福韦二吡呋酯耐药(基因型和表型分析)相关的特"}, {"probability": {"variance": 3e-06, "average": 0.998657, "min": 0.996142}, "location": {"width": 70, "top": 493, "height": 25, "left": 214}, "words": "定突变"}, {"probability": {"variance": 0, "average": 0.779507, "min": 0.779507}, "location": {"width": 56, "top": 549, "height": 35, "left": 994}, "words": "世"}, {"probability": {"variance": 0.026076, "average": 0.719133, "min": 0.515888}, "location": {"width": 143, "top": 587, "height": 51, "left": 962}, "words": "长到对"}], "language": 3}